Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lupus News

EULAR Highlights The Impact Of Lupus On Patients' Lives

Main Category: Lupus
Article Date: 14 Jun 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 and a half stars

4.5 (2 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Results from an international online survey, carried out by UCB in conjunction with Lupus Europe and the Lupus Foundation of America, the two principal advocacy groups that represent people with lupus, were presented during the EULAR (European League Against Rheumatism) congress at a symposium called, "Lupus - considering the future."

Professor David Isenberg (Professor of Rheumatology at University College Hospital London), the symposium chairman, commented "Lupus is unpredictable, for some people the effects are more benign but for others, as the survey shows, the disease can have a huge detrimental impact. For all patients, lupus specialists should work via a multi-disciplinary approach tailoring care to the individual needs of the patient." He continued "Because lupus is a complex disease affecting multiple body systems, the development of effective drugs with a favourable risk:benefit profile is a major challenge - the new biological treatments seem to offer hope but we must wait until the results of ongoing trials are known."

Although not a scientific random sample of the patient population at large, the results provide an insight into the impact lupus has on individuals affected by the disease. The survey was completed by more than 1000 people living with lupus. Lupus can also be called systemic lupus erythematosus or SLE.

People with lupus from Europe and the U.S. reported that the three areas where the disease most significantly impacts their lives were career, physical well being and everyday activities. Forty five percent of the survey respondents in Europe cited career as the area where lupus had a highly significant affect, almost mirroring the 44% reported by respondents in the U.S. Twenty-eight percent of the European respondents (n=85) and 29% of those in the U.S. (n=154) reported being not employed due to lupus. Fifty-two percent of people with lupus from Europe (n= 162) and 50% (n=268) in the U.S. reported that their disease caused them to miss work from one day to more than 30 days of absence.

Similar findings were observed in the affect of lupus on physical well being with 41% of sufferers in Europe and 49% in U.S. reporting that lupus highly significant affected their physical well-being. Fatigue was the most common symptom reported by 85% of people from Europe (n= 277) and 95% from U.S. (n= 512), followed by arthritis and muscle pain with responses of 83% coming from Europe (n= 270) and 91% from U.S. (n=492). Negative impact on everyday life activities was the third most reported effect of lupus, with impacts such as the ability to go shopping and difficulty in commencing activity following waking up. Thirty-one percent of European respondents cited lupus as having a highly significant affect on this compared to 42% of U.S. respondents.

There have been no new dedicated treatments for lupus in the past 50 years. At present, NSAIDs (Non-steroidal anti-inflammatory drugs), antimalarials, corticosteroids and cytotoxics/immunosuppressants, are the main therapies used in the management of lupus.

Europe

-- 78% reported that lupus has affected their career (n=311):
1. 45% highly significant affect, 18% noticeable affect, 15% slight affect

1. 28% not employed due to lupus (n=85)

2. 52% are absent from work for between 1-30 days due to lupus (n=162)

-- 89% reported that lupus has affected their physical well-being (n=322):
1. 41% highly significant affect, 31% noticeable affect, 17% slight affect

-- 85% reported that lupus has affected their ability to do everyday tasks e.g. go shopping, get up in the morning (n=311):
1. 31% highly significant affect, 28% noticeable affect, 26% slight affect

1. 85% experience fatigue (n=277) and 67% (n=218) report fatigue as the most severe symptom of lupus

2. 83% experience arthritis and muscle pain/weakness (n=270) and 63% (n=204) report arthritis and muscle pain as the second most severe symptom of lupus

US

-- 84% reported that lupus has affected their career (n=551):
1. 44% highly significant affect, 21% noticeable affect, 19% slight affect

3. 29% not employed due to lupus (n=154)

4. 50% are absent from work for between 1-30 days due to lupus (n=268)

-- 95% reported that lupus has affected their physical well-being (n=556):
1. 49% highly significant affect, 32% noticeable affect, 14% slight affect

-- 91% reported that lupus has affected their ability to do everyday tasks e.g. go shopping, get up in the morning (n=550):
1. 42% highly significant affect, 30% noticeable affect, 19% slight affect

3. 95% report fatigue as a common symptom of lupus (n=512)

4. 91% reported arthritis, muscle pain/weakness as a common symptom of lupus (n=492)

Source
UCB




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Lupus Drug Benlysta Effective In Phase 3 Trials
20 Jul 2009
In what has been described as the first lupus drug in decades to show effectiveness in phase 3 clinical trials, the announcement that Benlysta (belimumab) outperformed placebo has surprised Wall Street, where many had...


Improving Health Care image Improving Health Care

Improvements are necessary to make sure Americans get the best quality health care and that money for this care is being spent as effectively as possible. Listen as experts -- both in government and in the private sector -- describe some of the steps taken to improve the health care system...

View more videos...